The FDA pulls key DEI initiative for cancer studies from its website
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
Hosted on MSN18h
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
The FDA has officially banned Red No. 3. Here are some products that contain the cancer-causing dye
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...
Hosted on MSN4d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthrough
A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
Healio2d
FDA expands Enhertu approval for breast cancer
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
Cure Today2d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
Healio8h
Decentralized clinical trials: FDA guidance and the ‘new modus operandi’
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
CNET3d
FDA Finally Bans Red Dye No. 3: What You Need to Know
The US Food and Drug Administration announced this month that it's effectively banning Red No. 3, the controversial ...
Could the FDA's recently approved Pap smear alternative reduce racial disparities in cervical cancer deaths?
Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...
Targeted Oncology2d
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
The American Journal of Managed Care2d
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.